Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow DTIL
Precision BioSciences, Inc. (DTIL) Piotroski F-score
Precision BioSciences, Inc.'s Piotroski F-score for fiscal 2025 is 1 out of 9: 1 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 1 | (3.00) |
| FY2024 | 4 | 1.00 |
| FY2023 | 3 | 2.00 |
| FY2022 | 1 | (4.00) |
| FY2021 | 5 | 3.00 |
| FY2020 | 2 | (1.00) |
| FY2019 | 3 | (1.00) |
| FY2018 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (31.45%) | 4.84% | Fail | 0 |
| Positive operating cash flow | (65.84m) | (58.44m) | Fail | 0 |
| Rising return on assets | (31.45%) | 4.84% | Fail | 0 |
| Cash flow above net income | (20.12m) | (65.61m) | Fail | 0 |
| Falling long-term leverage | 0.15 | 0.15 | Fail | 0 |
| Rising current ratio | 13.32 | 6.34 | Pass | 1 |
| No new shares issued | 12,826,000 | 6,833,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.24 | 0.46 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 1 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CHRS Coherus Oncology, Inc. compare | 6 |
| WHWK Whitehawk Therapeutics, Inc. compare | 4 |
| ADAG Adagene Inc. Sponsored ADR compare | 4 |
| DTIL Precision BioSciences, Inc. | 1 |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0 |
| CMPX Compass Therapeutics, Inc. compare | — |
| ORMP Oramed Pharmaceuticals Inc. compare | — |
| VRXA Veraxa Biotech AG compare | — |
| PEPG PepGen, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover